{"id":990221,"date":"2026-08-05T08:51:55","date_gmt":"2026-08-05T12:51:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag\/"},"modified":"2026-08-05T08:51:55","modified_gmt":"2026-08-05T12:51:55","slug":"onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag\/","title":{"rendered":"Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <i>Proteomedix Co-Founder and Proclarix\u00ae Co-Developer Returns to Company\u2019s Board; Thomas Meier, PhD Re-Elected as Chairman at Annual General Meeting<\/i>\n      <\/p>\n<p align=\"justify\">\n        <strong>CINCINNATI, Ohio , Aug.  05, 2026  (GLOBE NEWSWIRE) &#8212; <\/strong> Onconetix, Inc. (Nasdaq: ONCO) (\u201cOnconetix\u201d or the \u201cCompany\u201d) today announced that its fully-owned Swiss subsidiary, Proteomedix AG (\u201cPMX\u201d), has appointed Ralph Schiess, PhD to the PMX Board of Directors. The appointment was approved at the PMX Annual General Meeting of Shareholders held on June 22, 2026, at which Thomas Meier, PhD was also re-elected to serve an additional one-year term as Chairman of the Board.<\/p>\n<p align=\"justify\">Dr. Schiess is a co-founder of Proteomedix AG and co-developer of Proclarix\u00ae, the Company\u2019s CE-IVD certified prostate cancer diagnostic blood test, which was developed at the Swiss Federal Institute of Technology (ETH Z\u00fcrich). He brings to the Board more than a decade of experience in world-class academic institutions in both the United States and Europe, as well as over 10 years of experience in the diagnostic industry, with a track record of successfully developing products from scientific prototypes to commercial products.<\/p>\n<p align=\"justify\">Dr. Schiess currently serves as founding Chief Executive Officer of ZH3D (Zurich Hub for Drug and Device Development) at the University of Z\u00fcrich. Previously, as CEO and co-founder of Proteomedix AG, he led the company\u2019s efforts to identify novel biomarker signatures with utility in prostate cancer diagnosis, prognosis, and therapy management, ultimately resulting in the development of Proclarix\u00ae. Proteomedix was subsequently acquired by Onconetix in December 2023. Dr. Schiess holds a Master of Science from the University of Z\u00fcrich, completed an internship at the Institute of Systems Biology in Seattle, and received a Doctorate in Science from the Swiss Federal Institute of Technology (ETH Z\u00fcrich).<\/p>\n<p align=\"justify\">\u201cWe are delighted to welcome Ralph back to Proteomedix in a Board capacity. As a co-founder and the original architect of Proclarix\u00ae, Ralph brings a depth of scientific and commercial knowledge that is unmatched,\u201d said Beat Rheiner, PhD, Chief Executive Officer of Proteomedix AG. \u201cHis experience taking diagnostics from the research stage to commercial products, combined with his ongoing work at the University of Z\u00fcrich, makes him an exceptional addition to our Board at this stage of the Company\u2019s development.\u201d<\/p>\n<p align=\"justify\">\u201cI am proud to rejoin Proteomedix as a member of the Board. Proclarix\u00ae was built on years of rigorous scientific work, and I believe it has an important role to play in improving how prostate cancer is diagnosed,\u201d stated Ralph Schiess, PhD, newly appointed Board Member of Proteomedix AG. \u201cI look forward to contributing to the next phase of the Company\u2019s growth and to supporting the team as it continues to expand access to this technology.\u201d<\/p>\n<p>\n        <b>About Onconetix, Inc.<\/b>\n      <\/p>\n<p align=\"justify\">Onconetix, Inc. (Nasdaq: ONCO) is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative oncology solutions. Onconetix owns Proclarix\u00ae, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union under the IVDR, which it anticipates will be marketed in the U.S. as a lab developed test through its license agreement with Labcorp. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DNzpq_kBaxs1MeFlFNFkptJlPlNRvbx_AjjIjRh9fVaDGMcCmll_lvXoDYT4WoXONWzs_skC-_Ys044R_BVKxtdCRYzGvVk5BRsDdJJdsrg=\" rel=\"nofollow\" target=\"_blank\">www.onconetix.com<\/a>.<\/p>\n<p>\n        <b>About Proteomedix AG<\/b>\n      <\/p>\n<p align=\"justify\">Proteomedix AG (PMX) is a fully owned Swiss subsidiary of Onconetix, Inc. focused on the development and commercialization of innovative diagnostic solutions for prostate cancer. PMX developed Proclarix\u00ae, a CE-IVD certified diagnostic blood test that, when used in combination with PSA, supports the early identification of clinically significant prostate cancer. PMX is headquartered in Switzerland. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nxZUPAmgUG-0KSAL_uqIL9IKKswa4kfwVKeWy-ep1H_ydxw91wygLpVHukwh5JZLsSVJWdS2iUJxXP-8rqKn3N2Y2sneqTgdtf1C2BFDI8Q=\" rel=\"nofollow\" target=\"_blank\">www.proteomedix.com<\/a>.<\/p>\n<p>\n        <b>Forward-Looking Statements<\/b>\n      <\/p>\n<p align=\"justify\">Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201cforecast,\u201d \u201cestimate,\u201d \u201cexpect,\u201d and \u201cintend,\u201d among others. These forward-looking statements are based on Onconetix\u2019s current expectations and actual results could differ materially. Investors should read the risk factors set forth in Onconetix\u2019s Annual Report on Form 10-K filed with the SEC on March 13, 2026, and periodic reports filed with the SEC on or after the date thereof. All forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof. Onconetix does not undertake an obligation to update or revise any forward-looking statement except as required by applicable law.<\/p>\n<p>\n        <b>Investor and Media Contact:<\/b>\n      <\/p>\n<p>Onconetix, Inc.<br \/>201 E. Fifth Street, Suite 1900<br \/>Cincinnati, OH 45202<br \/>Phone: (513) 620-4101<br \/>Email:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DhzWH3S7V528QugqazozVL_N48-iiMY7Ub_PhC9tzcymjpD3Suil2RvspOUNu8bY_ISEgX4-r4I3cmnrUqeH60b8pNJvMlSEcP-Q5yjn0u4Y-fIT6Jds2laZC86jEAQD\" rel=\"nofollow\" target=\"_blank\">investors@onconetix.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNDEwNCM3NzYwMDI5IzUwMDEyNjMzNw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OGUyYzM2MDktYzE5My00Yjk4LTg4ZjEtMzg0OGM5YzA3MjMzLTUwMDEyNjMzNy0yMDI2LTA4LTA1LWVu\/tiny\/Onconetix-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Proteomedix Co-Founder and Proclarix\u00ae Co-Developer Returns to Company\u2019s Board; Thomas Meier, PhD Re-Elected as Chairman at Annual General Meeting CINCINNATI, Ohio , Aug. 05, 2026 (GLOBE NEWSWIRE) &#8212; Onconetix, Inc. (Nasdaq: ONCO) (\u201cOnconetix\u201d or the \u201cCompany\u201d) today announced that its fully-owned Swiss subsidiary, Proteomedix AG (\u201cPMX\u201d), has appointed Ralph Schiess, PhD to the PMX Board of Directors. The appointment was approved at the PMX Annual General Meeting of Shareholders held on June 22, 2026, at which Thomas Meier, PhD was also re-elected to serve an additional one-year term as Chairman of the Board. Dr. Schiess is a co-founder of Proteomedix AG and co-developer of Proclarix\u00ae, the Company\u2019s CE-IVD certified prostate cancer diagnostic blood test, which was developed at the Swiss &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-990221","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Proteomedix Co-Founder and Proclarix\u00ae Co-Developer Returns to Company\u2019s Board; Thomas Meier, PhD Re-Elected as Chairman at Annual General Meeting CINCINNATI, Ohio , Aug. 05, 2026 (GLOBE NEWSWIRE) &#8212; Onconetix, Inc. (Nasdaq: ONCO) (\u201cOnconetix\u201d or the \u201cCompany\u201d) today announced that its fully-owned Swiss subsidiary, Proteomedix AG (\u201cPMX\u201d), has appointed Ralph Schiess, PhD to the PMX Board of Directors. The appointment was approved at the PMX Annual General Meeting of Shareholders held on June 22, 2026, at which Thomas Meier, PhD was also re-elected to serve an additional one-year term as Chairman of the Board. Dr. Schiess is a co-founder of Proteomedix AG and co-developer of Proclarix\u00ae, the Company\u2019s CE-IVD certified prostate cancer diagnostic blood test, which was developed at the Swiss &hellip; Continue reading &quot;Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-05T12:51:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNDEwNCM3NzYwMDI5IzUwMDEyNjMzNw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG\",\"datePublished\":\"2026-08-05T12:51:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag\\\/\"},\"wordCount\":753,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwNDEwNCM3NzYwMDI5IzUwMDEyNjMzNw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag\\\/\",\"name\":\"Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwNDEwNCM3NzYwMDI5IzUwMDEyNjMzNw==\",\"datePublished\":\"2026-08-05T12:51:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwNDEwNCM3NzYwMDI5IzUwMDEyNjMzNw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwNDEwNCM3NzYwMDI5IzUwMDEyNjMzNw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag\/","og_locale":"en_US","og_type":"article","og_title":"Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG - Market Newsdesk","og_description":"Proteomedix Co-Founder and Proclarix\u00ae Co-Developer Returns to Company\u2019s Board; Thomas Meier, PhD Re-Elected as Chairman at Annual General Meeting CINCINNATI, Ohio , Aug. 05, 2026 (GLOBE NEWSWIRE) &#8212; Onconetix, Inc. (Nasdaq: ONCO) (\u201cOnconetix\u201d or the \u201cCompany\u201d) today announced that its fully-owned Swiss subsidiary, Proteomedix AG (\u201cPMX\u201d), has appointed Ralph Schiess, PhD to the PMX Board of Directors. The appointment was approved at the PMX Annual General Meeting of Shareholders held on June 22, 2026, at which Thomas Meier, PhD was also re-elected to serve an additional one-year term as Chairman of the Board. Dr. Schiess is a co-founder of Proteomedix AG and co-developer of Proclarix\u00ae, the Company\u2019s CE-IVD certified prostate cancer diagnostic blood test, which was developed at the Swiss &hellip; Continue reading \"Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-05T12:51:55+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNDEwNCM3NzYwMDI5IzUwMDEyNjMzNw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG","datePublished":"2026-08-05T12:51:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag\/"},"wordCount":753,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNDEwNCM3NzYwMDI5IzUwMDEyNjMzNw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag\/","name":"Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNDEwNCM3NzYwMDI5IzUwMDEyNjMzNw==","datePublished":"2026-08-05T12:51:55+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNDEwNCM3NzYwMDI5IzUwMDEyNjMzNw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNDEwNCM3NzYwMDI5IzUwMDEyNjMzNw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/onconetix-announces-appointment-of-ralph-schiess-phd-to-board-of-directors-of-proteomedix-ag\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/990221","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=990221"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/990221\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=990221"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=990221"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=990221"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}